No abstract

No abstract

report on the efficacy and tolerability of Truxima and its cost saving benefit. Aims: This is a multi-centre study to evaluate the safety and overall response rate of Truxima in combination with chemotherapy in patient with an underlying haematological malignancy Methods: This is a local study conducted in London North West Hospital from 1 st of October 2017 to 1 st of April 2018 on patients who received Truxima with or without chemotherapy for B cell malignancy Results: There were 42 patients who received Truxima and 57% (24 out of 42) had a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL). Truxima were generally well tolerated and 90% (38 out of 42) complication the infusion without any complications. There were three patients (7%) who experienced mild IRR which were all grade 2 or less. Amongst the patients who were diagnosed with Diffuse Large B Cell Lymphoma 33% (7 out of 21) achieved complete remission Summary/Conclusion: There were no specific concerns with Truxima as it has shown clinical similarity to MabThera in terms efficacy and safety. Truxima is 10% cheaper per 100 mg in comparison to Mabthera (£314.33 Vs £349.25), therefore it has the advantage of significant budget savings. In the current economic climate, these savings can have a significant impact on health gains at both patient and societal levels.

No abstract